Evidence map›Paper›PMID 42292743›Full record

ReviewStem cells international2026

Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β-Cell Regeneration, Immune Modulation, and Exosome-Mediated Glucose Homeostasis.

Jia Yang, Yinglong Chen, Huanmei Jing, Chang Liu, Xiaoling Chen, Jiaju Chu, Liyun Chen, Shijie Tang, Fei Yu, Wancong Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jia YangDepartment of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.
Yinglong ChenGuangdong Provincial Key Laboratory of Marine Biotechnology, Department of Biology, College of Science, Shantou University, Shantou, 515063, Guangdong, China, stu.edu.cn.ORCID https://orcid.org/0009-0008-5482-6680
Huanmei JingDepartment of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.
Chang LiuDepartment of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.
Xiaoling ChenDepartment of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.
Jiaju ChuDepartment of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.
Liyun ChenDepartment of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.
Shijie TangDepartment of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.ORCID https://orcid.org/0000-0002-5413-8828
Fei YuDepartment of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.
Wancong ZhangDepartment of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.ORCID https://orcid.org/0000-0003-4243-0327

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance, and a progressive decline in pancreatic β-cell function, leading to impaired glucose regulation. It is often accompanied by severe complications, including cardiovascular diseases, nephropathy, and retinopathy. Conventional treatments, such as sulfonylurea pills, insulin injections, and GLP-1 receptor agonist injections, provide transient glycemic control but are often costly with unstable efficacy and long-term side effects. Pancreatic islet transplantation, while effective in some cases, is limited by donor scarcity, graft rejection, and the need for lifelong immunosuppression. Recently, mesenchymal stem cells (MSCs) have emerged as a promising alternative due to their multipotent differentiation potential, immunomodulatory properties, and regenerative capabilities. This review examines the therapeutic roles of MSCs in β-cell regeneration, inflammation modulation, and tissue repair while also addressing key challenges in clinical translation. However, given the lack of long-term clinical data, the conclusions presented remain preliminary and should be interpreted with caution. This article, therefore, aims to provide a foundational reference for future research, rather than definitive clinical guidance.

Indexed as

stem cellsT2DMtissue engineeringβ-cell repair

Identifiers

PMID42292743
PMCPMC13263637

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.